| Mepha Pharma AG - Octreotid-Mepha LA 20 mg, Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension |
| 67154 | | 02 | | Octreotid-Mepha LA 20 mg | | Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension | | H01CB02 | | Octreotide | | 19.07.2019 | | |
|
| Composition |
| Praeparatio sicca: octreotidum 20 mg ut octreotidi acetas, poly(lactidum-co-glycolidum), mannitolum, pro vitro.
Solvens: carmellosum natricum corresp. natrium 1.512 mg, mannitolum, poloxamerum 188, aqua ad iniectabile q.s. ad solutionem pro 2 ml. |
| Packungsbestandteile |
| Lyophilisate and solvent | | | | | | | | Active Agent | Dose | additional_information |
|---|
| Octreotide | 20 mg | Praeparatio sicca |
| | BAG: Active Agent | Dose |
|---|
| Octreotide | 20 mg |
| | | | Inactive agents |
|---|
| Mannitol | | Poly(Lactidum-Co-Glycolidum) |
| |
| Solvens | | | Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension | | | | | | | | | BAG: Active Agent | Dose |
|---|
| Octreotide | 20 mg |
| | | | Inactive agents | Dose |
|---|
| Carmellose Sodium | | | Mannitol | | | Poloxamer | 188 |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 002 | | | | | | Yes |
|
